- A Phase II Study of Cetuximab (Erbitux(R)) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
-
Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Lee SS, Kim MK, Sym SJ, Lee JS, Kang YK
- KMID: 1785796
- J Korean Med Sci.
- 2007 Sep;22(Suppl):S98-S103.
- doi: 10.3346/jkms.2007.22.S.S98
We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers. From September 2004 to February 2006, 31 patients with metastatic colorectal cancer were... -
- CITED
-
- Close
- SHARE
-
- Close
